Edition:
United States

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

8.56USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$8.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,201
52-wk High
$17.11
52-wk Low
$4.63

Chart for

About

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of... (more)

Overall

Beta: 0.00
Market Cap(Mil.): $269.34
Shares Outstanding(Mil.): 30.61
Dividend: --
Yield (%): --

Financials

  SVRA.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -2.39 -- --
ROI: -83.31 -7.38 12.74
ROE: -113.07 -10.11 14.64

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 09 2018

BRIEF-Savara Reports Q4 Loss Per Share $0.23

* SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 14 2018

BRIEF-Savara Initiates Phase 2A Clinical Study Of Molgradex For The Treatment Of Ntm Lung Infection

* SAVARA INITIATES PHASE 2A CLINICAL STUDY OF MOLGRADEX FOR THE TREATMENT OF NTM LUNG INFECTION Source text for Eikon: Further company coverage:

Mar 13 2018

BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.

* SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S.

Feb 12 2018

BRIEF-Savara ‍Received $5 Mln Award For Development Of Aerovanc​

* SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​ Source text for Eikon: Further company coverage:

Nov 29 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.97 +0.25
Johnson & Johnson (JNJ.N) $123.45 +0.54
Roche Holding Ltd. (ROG.S) CHF219.40 +0.15
Roche Holding Ltd. (RO.S) CHF224.00 +0.60
Sanofi SA (SASY.PA) €66.14 -0.09
GlaxoSmithKline plc (GSK.L) 1,501.00 -6.60

Earnings vs. Estimates